Background check {#Sec1}
================

Urinary tract infection (UTI) is an infection involving urinary tract structures \[[@CR1]\]. The urinary tract can be infected in different ways, but the ascent of bacteria from the urethra is the common pathway \[[@CR2]\]. Urinary tract infection is the most common public health problem worldwide with women are more likely to be infected due to proximity of the urethral opening to the anus, the presence of vagina, and the shorter length of the urethra \[[@CR3], [@CR4]\]. Furthermore, pregnancy facilitates UTIs because of urinary retention in the bladder, increased calyceal and ureteral dilation, and increased levels of urinary glucose and amino acids \[[@CR5]\]. Urinary tract infection during pregnancy can cause many complications \[[@CR6]--[@CR8]\]. To prevent these complications, during pregnancy, UTI should be treated \[[@CR7]--[@CR12]\]. However, this high occurrence of UTI in pregnancy could increase the prevalence of inappropriate antibacterial treatment, which in turn increases antibiotic resistance (ABR) \[[@CR13]\].

Antibiotic resistance is a growing problem across the world, and indiscriminate use of drugs increases its evolution \[[@CR14], [@CR15]\]. It is known that antibiotics are used to clear infection causing bacteria, however, their usage increases the prevalence of antibiotic-resistant strains via selective pressure where antibiotics kill susceptible strains and leave the resistant one to multiply \[[@CR16], [@CR17]\]. Production of enzymes is a well-known mechanism that the bacteria are using to resist antibiotics \[[@CR18], [@CR19]\]. Extended-spectrum β-lactamases (ESβLs) producing strains can easily hydrolyze β-lactam agents but inhibited by β-lactamase inhibitors \[[@CR20]\]. These organisms also carry genes encoding resistance to other classes of antibiotics. As a result, most of them are classified as multi-drug resistant (MDR) organisms \[[@CR19]\]. The enzymes and other ABR determinants of a drug-resistant bacteria can also be transferred to drug-susceptible strains \[[@CR21]\]. Furthermore, there is a report that these drug-resistant bacteria or genes codes for drug resistance can be transmitted vertically from mothers to their neonates \[[@CR22]\]. Urinary tract infections during pregnancy are commonly caused by Gram-negative bacteria, with *Enterobacteriaceae*, in particular, *E. coli* accounted for about 90% of these infections \[[@CR23]\]. During pregnancy, untreated UTIs or UTIs caused by MDR or drug-resistant strains like ESβLs are associated with many problems, including the development of pyelonephritis and cystitis in the mother, pre-eclampsia, preterm delivery, low birth weight infant, and cesarean deliveries \[[@CR24]--[@CR26]\]. Multi-drug resistant organisms are associated with history of hospitalization, previous use of any antibiotics, chronic underlying diseases, use of urinary catheters, and previous history of UTIs. \[[@CR27]\].

In Ethiopia, UTI among pregnant women is very common with a reported prevalence between 9.2% and 18.8%; *Enterobacteriaceae* are the leading isolates responsible for the infection \[[@CR28]--[@CR33]\]. The WHO global report has revealed the overall epidemiology of ESβL producing bacteria has not been well known in resource-limited countries like Ethiopia \[[@CR34]\]. Therefore, this study was aimed at determining MDR and ESβL production in bacterial uropathogens isolated from pregnant women, and identifying associated risk factors for MDR bacterial infection.

Methods {#Sec2}
=======

Study area, design and period {#Sec3}
-----------------------------

A hospital-based cross-sectional study was conducted from March to May 2017 at the University of Gondar Hospital (UoGH), Northwest Ethiopia. This referral teaching hospital is one of the biggest hospitals in the Amhara region. About five million people, from the surrounding areas, visit this hospital for different medical services. The study population was pregnant women, who were not on antibiotic treatment for the last 2 weeks from the data collection day, visiting the ANC unit of the hospital.

Sample size and sampling technique {#Sec4}
----------------------------------

The sample size of this study was 384. Since there is no clear data on the prevalence of ESβLs producing strains or MDR bacteria among pregnant women, a single population proportion formula, taking p as 50%, was used to calculate the sample size. The systematic sampling technique was applied to select the study participants. Sampling interval was calculated from the sampling frame, estimated number of ANC attendants during the study period. The first study participant was selected using lottery method.

Data collection procedure {#Sec5}
-------------------------

All the study participants were interviewed face to face by trained data collectors (midwives), using a structured and pretested questionnaire, to collect data on the socio-demographic, clinical, and pregnancy-related characteristics. Finally, instruction on how to collect clean-catch midstream urine samples was given to the pregnant women; \~10--20 ml of urine specimen was collected using a sterile screw-capped, wide-mouthed container. The container was labeled with unique code, date, and time of collection then sent to the microbiology laboratory for processing and testing \[[@CR35]\].

Culture and identification technique {#Sec6}
------------------------------------

The urine specimen was first inoculated on Cysteine-Lactose-Electrolyte-Deficient (CLED) agar using a sterile loop measuring 10 µl then later colonies from CLED agar were subjected to gram staining procedure and then sub-cultured on MacConkey and Blood agar plates (Oxoid, UK). The plates were incubated in the appropriate atmosphere at 37 ℃ for 24--48 h overnight. A colony count of ≥ 10^5^ CFU/ml of urine was considered as significant bacteriuria. The identification of the culture-grown bacteria was based on the gram staining, colony characteristics, and biochemical reactions \[[@CR35]\]. The Analytical Profile Index (API 20E) was used to support the bacterial identification process (bioMerieux, France).

Drug susceptibility testing (DST) {#Sec7}
---------------------------------

Antibiotic susceptibility testing was carried out using the disc diffusion method. The bacterial suspension was made; its turbidity was adjusted to a 0.5 McFarland turbidity standard before inoculated over the entire surface of Muller Hinton agar \[[@CR35]\]. In this study, the following antibiotic discs were used: for Gram-negative bacteria, ampicillin (10 µg), cephalothin (30 µg), nalidixic acid (30 µg), cefepime (30 µg), augmentin (30 µg), ceftazidime (30 µg), cefotaxime (30 µg), cefixime (5 µg), ceftriaxone (30 µg), cefuroxime (30 µg), and cefpodoxime (10 µg); for gram-positive bacteria, cotrimoxazole (1.25/23.75 µg), gentamicin (10 µg), amikacin (30 µg), tetracycline (30 µg), chloramphenicol (30 µg), doxycycline (30 µg), penicillin (10 units), and erythromycin (15 µg), and for both classes of bacteria, cefoxitin (30 µg), norfloxacin (10 µg), ciprofloxacin (5 µg) and nitrofurantoin (300 µg). The zone diameter was interpreted according to the Clinical and Laboratory Standards Institute (CLSI) \[[@CR36]\]. Bacterial isolates were regarded as MDR when they were resistant to one or more antibiotics in three or more classes of antimicrobials that the isolate is expected to be susceptible.

Extended-spectrum β-lactamases detection {#Sec8}
----------------------------------------

All isolates showing reduced susceptibility to either of the 3rd generation cephalosporins (Cefpodoxime zone: ≤ 17 mm; Ceftazidime zone: ≤ 22 mm; Cefotaxime zone: ≤ 27 mm; Ceftriaxone zone: ≤ 25 mm) were selected using disc diffusion method. Those isolates then subjected to a phenotypic confirmatory test for ESβLs detection \[[@CR37]\]. A combination disc test was used based on CLSI 2017 recommendations \[[@CR37]\]. Cefotaxime (30 µg), ceftazidime (30 µg), ceftazidime-clavulanate (30/10 µg) and cefotaxime-clavulanate (30/10 µg) discs were plated on MHA that was inoculated with a single bacterial suspension. After overnight incubation, 16--18 h at 37 °C, a ≥ 5 mm increase in zone diameter of cefotaxime-clavulanate and/or ceftazidime-clavulanate than the zone diameter of cefotaxime and/or ceftazidime was taken as positive for the presence of ESβLs in bacterial isolates.

Quality control {#Sec9}
---------------

A pre-tested and structured questionnaire was used to collect socio-demographic, pregnancy, and clinical-related factors. Standard Operating Procedures (SOPs) were strictly followed during all the stages of sample collection and laboratory work. Reference strains used in this study were *E. coli* ATCC 25922, *P. aeruginosa* ATCC 27853, and *S. aureus* ATCC 25923. The sterility of the prepared media was checked by incubating 5% of the batch overnight at 37 °C. For ESβL positive control, *K. pneumoniae* ATCC 700603, and ESβL negative control, *E. coli* ATCC 25922 strains were used \[[@CR37]\].

Data processing and analysis {#Sec10}
----------------------------

The data was entered into SPSS version 20 and was double-checked before analysis. Appropriate descriptive statistics for demographic, clinical, and pregnancy-related characteristics were calculated. The bivariable logistic regression model was fitted for each independent variable. Moreover, those variables having a p-value \< 0.2 in univariate analysis were fitted into the multivariable logistic regression model. Odds ratio with a 95% confidence interval and p-values were used to measure the strength of association and to identify statistically significant associated factors, respectively. In multivariable analysis, variables having a p-value \< 0.05 were considered to have a statistically significant association with MDR bacterial infection.

Results {#Sec11}
=======

Socio-demographic characteristics {#Sec12}
---------------------------------

A total of 384 pregnant women were participated in the present study with the age ranges of 15--45 and a mean (standard deviation) age of 26 (± 5.4). About 349 (90.9%) of the study participants were Orthodox Christians, 305 (79.4%) were urban, and 365 (95%) were married. About 128 (33%) of the participants were illiterate, 167 (43.5%) were housewives, and 110 (28.6%) had monthly income ≤ 1000 birr (Table [1](#Tab1){ref-type="table"}).Table 1Socio demographic characteristics of the study groupsSocio-demographic characteristicsFrequencyPercentageAge (in years) 15--19215.5 20--2412733.1 25--2914136.7 30--345113.3 \> 344411.5Religion Orthodox34990.9 Muslim318.1 Protestant20.5 Others20.5Residence Urban30579.4 Rural7920.6Marital status Currently single194.9 Currently married36595.1Level of education Not read and write12833.3 Primary7118.5 Secondary9925.8 College/university8622.4Occupation House wife16743.5 Farmer379.6 Merchant4612 Employed9625 Daily labourer215.5 Others174.4Monthly income (in birr) ≤ 100011028.6 1000--18008622.4 1801--28009825.5 ≥ 28019023.4

Pregnancy and clinical related factors {#Sec13}
--------------------------------------

Among the study participants, 190 (49.5%) and 119 (31%) were on their 3rd and 2nd trimester, respectively. Based on parity, 224 (58.3%) of the women had more than one pregnancy experience, and 176 (45.8%) of them were nulliparous. Of the total study participants, 26 (6.8%) had a history of prior hospitalization, 62 (16.1%) had a history of previous UTI, and 88 (22.9%) had prior antibiotic therapy. 3.4% of pregnant women had HIV infection. The number of pregnant women with a symptom/s of UTI was 122 (31.8%) (Table [2](#Tab2){ref-type="table"}).Table 2Pregnancy and clinical related factors among the study groupPregnancy related characteristicsFrequencyPercentageGestation period \< 3 months5514.3 3--6 months11931 \> 6 months19049.5 Don't know205.2No of pregnancy Prim-gravida16041.7 Multi-gravida22458.3No of times giving birth Nulliparous17645.8 Primiparous9825.5 Multiparous11028.6Previous hospitalization266.8History of UTI6216.1Antibiotic therapy8822.9HIV positive133.4Participant status for UTI Symptomatic12231.8 Asymptomatic26268.2

Prevalence of urinary tract infection among the study group {#Sec14}
-----------------------------------------------------------

The overall prevalence of UTI among study participants was 61 (15.9% (95% CI 12.8--20.1%)). Of isolated uropathogens, *E. coli* 30 (49.2%) was the commonest uropathogen, followed by CoNS 17 (27.9%) and *S. aureus* 11 (18%). The prevalence of MDR among uropathogens was 37 (60.65%). About 13 (76.47%) of the CoNS and 17 (56.67%) of the *E. coli* isolates were MDR. The prevalence of ESβLs production among *Enterobacteriaceae* was 6 (18.2%). *E. coli* and *Enterobacter cloacae* were the two ESβL producing isolates. Among Gram-positive isolates, 4 (36.36%) of the *S. aureus* were MRSA, and 8 (47.06%) of the CoNS were resistant to methicillin (Table [3](#Tab3){ref-type="table"}).Table 3The prevalence of MDR, ESβLs producing and MR (Methicillin resistant) bacteria among uropathogens isolated from the study groupIsolatesNumber (%)Frequency and percentage (prevalence)MDRESβLMR*E. coli*30 (49.2%)17 (56.67%)5 (16.67%)--*K. pneumoniae*2 (3.3%)1 (50%)0--*E. cloacae*1 (1.6%)1 (100%)1 (100%)--*S. aureus*11 (18%)5 (45.45%)--4 (36.36%)CoNS17 (27.9%)13 (76.47%)--8 (47.06%)Total61 (100%)37/61 (60.65%)6/33 (18.18%)12/28 (42.85%)MDR, multi-drug resistant; ESβL, extended spectrum β-lactamase; MR, methicillin resistant

The prevalence of UTI among symptomatic and asymptomatic cases was 38/122 (31.1%) and 23/262 (8.8%), respectively. The Fisher's exact test showed that history of hospitalization, previous history of UTI, and prior antibiotic therapy were associated with the presence of UTI. The prevalence of MDR bacteria was 25/38 (65.8%) and 12/23 (52.2%) among culture-positive symptomatic and asymptomatic participants, respectively. The prevalence of MDR was significantly higher (p \< 0.05) among study participants who had a history of antibiotic therapy than those who hadn't. (Table [4](#Tab4){ref-type="table"}).Table 4Pregnancy and clinical related factors against significant bacteriuria and MDR bacteria among pregnant womenVariablesSignificant bacteriuriaMDR bacteriaYesNoTotalp- valueYesNoTotalp- valueGestation period \< 3 months6 (10.9%)49 (89.1%)550.2193 (50%)3 (50%)60.808 3--6 months24 (20.2%)95 (79.8%)11915 (62.5%)9 (37.5%)24 \> 6 months30 (15.8%)160 (84.2%)19018 (60%)12 (40%)30 Don't know1 (5%)19 (95%)201 (100%)01No of Pregnancy Prim-gravida29 (18.1%)131 (81.9%)1600.38321 (72.4%)8 (27.6%)290.127 Multi-gravida32 (14.3%)192 (85.7%)22416 (50%)16 (50%)32No of times giving birth Nulliparous31 (17.6%)145 (82.4%)1760.50121 (67.7%)10 (32.3%)310.492 Primiparous12 (12.2%)86 (87.8%)986 (50%)6 (50%)12 Multiparous18 (16.4%)92 (83.6%)11010 (55.6%)8 (44.4%)18Hospitalization Yes15 (57.7%)11 (42.3%)26*\< 0.001*10 (66.67%)5 (33.3%)150.807 No46 (12.8%)312 (87.2%)35827 (58.7%)19 (41.3%)46History of UTI Yes27 (43.5%)35 (56.5%)62*\< 0.001*20 (74.07%)7 (25.93%)270.099 No34 (10.6%)288 (89.4%)32217 (50%)17 (50%)34Antibiotic therapy Yes27 (30.7%)61 (69.3%)88*\< 0.001*22 (81.5%)5 (18.5%)27*0.007* No34 (11.5%)262 (88.5%)29615 (44.12%)19 (55.88%)34HIV Yes4 (30.8%)9 (69.2%)130.1353 (75%)1 (25%)41 No57 (15.4%)314 (84.6%)37134 (59.65%)23 (40.35%)57Participant status for UTI Symptomatic38 (31.1%)84 (68.9%)122*\< 0.001*25 (65.8%)13 (34.2%)380.433 Asymptomatic23 (8.8%)239 (91.2%)26212 (52.2%)11 (47.8%)23The percentage displayed under positive culture and MDR was calculated using the frequency of each classes of the variable group that were enrolled in this study and positive for culture as a denominator, respectivelyItalic values means the observed difference is statistically significant (p \< 0.05)MDR, multi-drug resistant; UTI, urinary tract infection; HIV, human immuno-deficiency virus

Antimicrobial susceptibility pattern {#Sec15}
------------------------------------

Only 2/61 (3.28%) of bacterial isolates were sensitive to all antibiotics used in this study. The 14 (22.95%), 16 (26.23%), and 19 (31.15%) of the isolates were resistant to two, three, and at least five of the antibiotics tested, respectively (Table [5](#Tab5){ref-type="table"}).Table 5Distribution of MDR among uropathogens isolated from the study groupIsolated organismsNumber of drugs affected by the isolateTotalR0R1R2R3R4R5*E. coli* (n = 30)2 (6.67%)1 (3.33%)8 (26.67%)10 (33.33%)2 (6.67%)7 (23.33%)30*K. pneumoniae* (n = 2)0 (0.0%)0 (0.0%)1 (50%)1 (50%)0 (0.0%)0 (0.0%)2*E. cloacae* (n = 1)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)1 (100%)1*S. aureus* (n = 11)0 (0.0%)3 (27.27%)3 (27.27%)2 (18.18%)1 (9.09%)2 (18.18%)11CoNS (n = 17)0 (0.0%)2 (11.76%)2 (11.76%)3 (17.65%)1 (5.88%)9 (52.94%)17Total (61)2 (3.28%)6 (9.84%)14 (22.95%)16 (26.23%)4 (6.56%)19 (31.15%)61R0, resistant to none (sensitive to all); R1, resistant to one; R2, resistant to two; R3, resistant to three; R4, resistant to four and R5, resistant to five and more antibiotics tested

A high number of *E. coli* isolates were resistant to ampicillin 27 (90%), cephalothin 25 (83.33%), and augmentin 17 (56.7%). None of the Gram-negative isolates were resistant to nitrofurantoin, and none of the Gram-positive isolates were resistant to gentamicin and amikacin. Among the Gram-positive isolates, *Staphylococcus saprophyticus* was the only one resistant to nitrofurantoin. The resistance rate for cefoxitin was 36.4% among *S. aureus*, and 47% among Coagulase Negative *Staphylococcus* (CoNS) isolates (Table [6](#Tab6){ref-type="table"}).Table 6Distribution of antibiotic resistance among uropathogens isolated from the study groupAntibiotics testedIsolated organisms (n = 61)Total (61)*Enterobacteriaceae* (n = 33)*E. coli* (n = 30)*K. pneumoniae* (n = 2)*E. cloacae* (n = 1)*S. aureus* (n = 11)CoNS (n = 17)Non-ESβLs (n = 27)ESβLs (n = 6)p-valueAUG17 (56.67%)1 (50%)1----19/33 (57.6%)15 (55.6%)4 (66.7%)0.618FEP6 (20%)01----7/33 (21.2%)1 (3.7%)6 (100%)*\< 0.001*CFM6 (20%)01----7/33 (21.2%)1 (3.7%)6 (100%)*\< 0.001*CRO5 (16.67%)01----6/33 (18.2%)0 (0.0%)6 (100%)*\< 0.001*FOX3 (10%)014 (36.36%)8 (47.05%)18/61 (26.2%)1(3.7%)3 (50%)0.014CXM5 (16.67%)01----6/33 (18.2%)0 (0.0%)6 (100%)*\< 0.001*AMP27 (90%)2 (100%)1----30/33 (90.9%)24 (88.9%)6 (100%)0.392NAL5 (16.67%)01----6/33 (18.2%)2 (7.4%)4 (66.7%)*0.005*CF25 (83.33%)2 (100%)1----28/33 (84.8%)22 (81.5%)6 (100%)0.556CPD5 (16.67%)01----6/33 (18.2%)0 (0.0%)6 (100%)*\< 0.001*CAZ5 (16.67%)01----6/33 (18.2%)0 (0.0%)6 (100%)**\< ***0.001*NOR4 (13.33%)001 (9.1%)8 (47.05%)13/61 (21.3%)2 (7.4%)2 (33.33%)0.142F00001 (5.9%)1/61 (1.64%)0 (0.0%)0 (0.0%)--CIP4 (13.33%)001 (9.1%)8 (47.05%)13/61 (21.3%)2 (7.4%)2 (33.33%)0.142CTX5 (16.67%)01----6/33 (18.2%)0 (0.0%)6 (100%)**\< ***0.001*GEN------000/28 (0.0%)------PEN------10 (90.9%)15 (88.2%)25/28 (89.3%)------TE------2 (18.18%)9 (52.9%)11/28 (39.3%)------COT------7 (63.63%)14 (82.35%)21/28 (75%)------AMK------000/28 (0.0%)------DOX------2 (18.18%)10 (58.82%)12/28 (42.68%)------C------3 (27.27%)9 (52.9%)12/28 (42.68%)------ERY------2 (18.18%)9 (52.9%)11/28 (39.3%)------Italic values means the observed difference is statistically significant (p \< 0.05)"--" Not done; AUG, amox-clavulanic acid; FEP, cefepime; CFM, cefixime; CRO, ceftriaxone; FOX, cefoxitin; CXM, cefuroxime; AMP, ampicillin; NAL, nalidixic acid; CF, cephalothin; CPD, cefpodoxime; CAZ, ceftazidime; NOR, norfloxacin; F, nitrofurantoin; CIP, ciprofloxacin; CTX, cefotaxime; PEN, penicillin; TE, tetracycline; COT, cotrimoxazole; AMK, amikacin; DOX, doxycycline; C, chloramphenicol, and ERY, erythromycin

The ESβLs producing isolates were 100% resistant to all the 3rd generation cephalosporin, cefuroxime, and cefepime. The difference was significant (p \< 0.001) when compared to resistance rates by non-ESβLs producing isolates. All the ESβLs and most of the non-ESβLs producing strains were resistant to ampicillin and cephalothin. Uropathogens producing ESβLs were sensitive to nitrofurantoin; most of them were susceptible to fluoroquinolones (Table [6](#Tab6){ref-type="table"}).

The only variable that remained an independent factor for the presence of MDR bacterial infection among pregnant women was a prior history of antibiotic therapy (OR = 5.164, 95% CI 1.226--21.758) (Table [7](#Tab7){ref-type="table"}).Table 7Bi-variable and multi-variable analysis of factors associated with the presence of MDR bacteriaVariableMDRCOR (95% CI)AOR (95% CI)YesNoOccupation House wife1665.867 (1.427--24.113)6.544 (1.005--42.616) Farmer727.700 (1.159--51.171)4.058 (0.277--59.49) Merchant542.750 (0.509--14.860)1.781 (0.197--16.066) Employed5111 Daily labourer214.400 (0.319--60.614)1.965 (0.40--97.385) Others20----Education Not read and write862.000 (0.456--8.777)1.442 (0.169--12.282) Primary1437.000 (1.386--35.345)2.558 (0.287--22.089) Secondary962.250 (0.522--9.697)0.915 (0.135--6.194) College and above691No of pregnancy Prim-gravida2181 Multi-gravida16160.381 (0.131--1.110)0.414 (0.092--1.855)History of UTI Yes2072.857 (0.959--8.516)2.687 (0.599--12.052) No17171Antibiotic therapy Yes2255.573 (1.706--18.205)5.164 (*1.226--21.758*)\* No15191Italic value means there is a statistical significance between independent and dependent variables (95% CI excludes the null value, which is 1)COR, crude odd ratio; AOR, adjusted odd ratio; CI, confidence interval(\*) p-value \< 0.05

Discussion {#Sec16}
==========

The high prevalence of UTI during pregnancy and fear of its complication on both mothers and their baby \[[@CR6], [@CR26]\] encourages the irrational use of antibiotics \[[@CR38]\], especially in the developing world where empirical treatment is prevalent. Knowing the prevalence of drug-resistant uropathogens among pregnant women could help the clinicians to improve the wise use of antibiotics during pregnancy.

The prevalence of UTI (15.9%) in this study was in agreement with previous studies in eastern Ethiopia (14%) \[[@CR33]\] and in Tanzania (14.6%) \[[@CR39]\]. But it was higher than the studies conducted in Bahir Dar (9.5%) by Tazebew D et al. \[[@CR31]\] and in Gondar (10.4%) by Alemu et al. \[[@CR29]\]. This difference might be due to the higher proportion of symptomatic study participants in the present study.

The most prevalent uropathogen identified was *E. coli* 49.2%, followed by CoNS 27.9% and *S. aureus* 18.03%. Previous reports from different regions of Ethiopia have also reported similar findings \[[@CR29], [@CR31], [@CR33]\]. The result, however, was slightly different from the study from Hawassa \[[@CR28]\], where CoNS were frequently isolated. This difference might be due to the difference in hygienic practices between study participants and climate and temperature factors.

In the present study, the prevalence of MDR bacteria was 60.65%. This study reported a lower prevalence than previous studies in the same study area, 68% in 2002 \[[@CR40]\], and 95% in 2012 \[[@CR29]\]. The lower prevalence may be due to differences in MDR definition and/or the antibiotics used for AST. Our prevalence was higher than the study result from Pakistan, where MDR prevalence was 37.9% \[[@CR41]\]. The lower prevalence seen in Pakistan may be due to the presence of male participants in the study.

The present study was also aimed to assess the prevalence of ESβLs production among *Enterobacteriaceae.* Hence, the prevalence of ESβLs was 18.2%. This prevalence was lower than previous reports in Ethiopia, which was between 25 and 38.4% \[[@CR42]--[@CR44]\]. Reasonably, difference in study setting, sampling protocol and study population could have an impact on the isolation rate of ESβLs. Likewise, the finding of this study was lower than the study done in India (25.2%) by Selvakumar et al. \[[@CR45]\]. On the other hand, it was higher than the study done in Nepal (7.3%) by Thapa et al. \[[@CR46]\] and Pakistan (5.8%) by Iqbal et al. \[[@CR41]\]. This difference of prevalence might be due to the difference in number of bacterial isolates, and geographical area.

At species level, this study revealed that the prevalence of ESβLs producing *E.coli* was 16.7% and it is incompatible with a report by Olufunke et al. in Nigeria \[[@CR21]\]. This prevalence was also lower than the previous study results in Ethiopia. For instance, 36% and 28.2% of ESβL producing *E. coli* was identified in Jimma by 2012 \[[@CR42]\] and 2015 \[[@CR43]\], respectively.

In the present study, about 90%, 84.8%, and 57.6% of gram-negative uropathogens were resistant to ampicillin, cephalothin, and augmentin, respectively. Previous reports from different parts of Ethiopia also showed a high resistance rate to ampicillin and augmentin \[[@CR30], [@CR31]\]. The possible explanation of ampicillin and augmentin resistance might be due to their extensive use in the health facilities as this may boost the selection of uropathogens harboring the β-lactamase enzyme, which can hydrolyze penicillin.

We reported that drugs like nitrofurantoin, gentamicin, and amikacin were effective against uropathogens, followed by norfloxacin and ciprofloxacin. Thapa et al. \[[@CR46]\] reported the same antibiotics as the effective drugs to treat bacterial UTIs. The current study also reported that ESβLs producing bacterial uropathogens were resistant to 9 out of 15 antibiotics tested, especially to 3rd generation cephalosporins. This finding was in line with previous studies done by Onwuezobe et al. in Nigeria \[[@CR47]\] and by Kumar Yadav et al. in Nepal \[[@CR48]\]. This higher antibiotic resistance rate among ESβLs producing isolates may be because of the presence of plasmid carrying genes other than those coding for ESβLs, which are responsible for resistant to other classes of antibiotics like fluoroquinolones.

In the present study, all ESβLs producing isolates were sensitive to the drug nitrofurantoin. The same thing happened in Nepal by Thapa et al. \[[@CR46]\] and Sri Lanka by Dissanayake et al. \[[@CR49]\]. This similarity in nitrofurantoin sensitivity rate between studies might be because of its narrow range of clinical indications, which results in less usage compared to other UTI drugs.

History of antibiotic usage was the only variable associated with the presence of MDR uropathogens. The previous study in Ethiopia also reported the use of antibiotics as a risk factor for acquiring MDR bacteria \[[@CR40]\]. Other studies were also reported antibiotic usage as a risk factor for the presence of ESβLs producing strains, which are usually MDR \[[@CR50], [@CR51]\].

The limitation and strength of the study {#Sec17}
----------------------------------------

The study was done in the hospital setting so that the result may not be representative of other pregnant women attending other health sectors in the same area. Associated factors for MDR bacterial infection were not fully addressed because of the absence of participants with factors like catheterization, and chronic diseases like diabetes mellitus. The number of isolates was small, and this may affect the estimation of the prevalence of ESβL producing strains among pregnant women.

Conclusion {#Sec18}
==========

Antibiotics like nitrofurantoin, ciprofloxacin, and norfloxacin were effective against gram-negative uropathogens, including ESβL producers. Gentamicin, amikacin, and nitrofurantoin were effective against staphylococcus species, which causes UTI. The prevalence of MDR was high among uropathogens, which calls for the use of AST results to treat UTI during pregnancy. The presence of Multi-drug resistant bacterial infection during pregnancy was associated with prior antibiotic therapy. The isolation of ESβLs producing uropathogens and methicillin-resistant staphylococcus species in this study calls for the need of periodic and continuous follow-up of antibiotic usage during pregnancy. Moreover, conducting molecular studies will help to characterize the various drug-resistant strains.
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SPSS

:   Statistical Package for Social Sciences

UTIs

:   Urinary tract infections
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